L-R: Keynote Speakers Joseph Loscalzo, MD, PhD and Nick Morrell, PhD, with Marlene Rabinovitch, MD
Ross Metzger, PhD checking in at the 4th International PH Symposium.
Vinicio de Jesus Perez, MD
Keynote Speaker: Joseph Loscalzo, MD, PhD, Harvard University
Keynote Speaker: Joseph Loscalzo, MD, PhD, Harvard University
James Spudich, PhD, Stanford University
Astrid Gillich, PhD presents at the 4th International PH Symposium
Tushar Desai, PhD presents at the 4th International PH Symposium
Emma Lundberg, PhD presents at the 4th International PH Symposium
Emma Lundberg, PhD presents at the 4th International PH Symposium
Despite numerous recent advances in pulmonary arterial hypertension (PAH), additional research is warranted to better understand disease pathogenesis, identify and deconstruct novel sources of biological and clinical heterogeneity across patients, and pave a road to new treatment paradigms.
More The exciting field of precision biology arms researchers with powerful tools to study PAH pathobiology, such as single cell transcriptomics, spatial proteomics, lineage tracing and the use of induced pluripotent stem cells to model disease in a dish. These cutting-edge methods have the potential to transform the way we understand disease pathogenesis, identify specific treatment targets, and develop precise and highly effective PAH therapies.
Precision medicine is a therapeutic strategy that takes into account individual variability in genes, environment, and lifestyle to identify clinical phenotypes that would specifically benefit from targeted therapies. The importance of precision medicine to the future of US health care has been stressed by president Obama in his Precision Medicine Initiative, which aims to provide clinicians with a way to integrate seemingly disparate data (e.g. genetics, proteomics, epigenetics, metabolomics, medical record data, etc.) into a framework that improves individual clinical outcomes and health care quality. Given the rapid advancement of high-throughput ‘Omics’ platforms, availability of sophisticated machine learning algorithms, and emergence of collaborative PAH biorepositories and phenotyping efforts, the time is ripe to discuss how state-of-the-art technologies can facilitate the translation of scientific discoveries into clinical tools for improved diagnosis and treatment of PAH patients.
Guest Faculty
Evan Brittain, MD
Vanderbilt University
Jane Leopold, MD
Brigham and Women's Hospital, Boston
Joseph Loscalzo, MD, PhD
Harvard University
Nick Morrell, MD
Cambridge University, UK
Christopher Rhodes, PhD
Imperial College, UK
Guest Panelists
Lena Bolivar
Former Patient
Derek Solum, PhD
United Therapeutics
Gayathri Swaminath, PhD
Merck
Stanford Faculty
Vinicio de Jesus Perez, MD (Co-Chair)
Pulmonary and Critical Care Medicine
Jeffrey Feinstein, MD, MPH
Pediatric Cardiology
Mingxia Gu, MD, MPH
Pediatric Cardiology
Rachel Hopper, MD (Symposium Committee)
Pediatric Cardiology
Purvesh Khatri, PhD
Biomedical Informatics
Mark Krasnow, MD, PhD
Biochemistry
Maya Kumar, PhD
Allergy and Asthma Research
Emma Lundberg, PhD
Genetics (Visiting Associate Professor)
Alison Marsden, PhD
Pediatric Cardiology
Ross Metzger, PhD
Pediatric Cardiology
Mark Nicolls, MD
Pulmonary and Critical Care Medicine
Marlene Rabinovitch, MD
Pediatric Cardiology
Edda Spiekerkoetter, MD (Co-Chair)
Pulmonary and Critical Care Medicine
James Spudich, PhD (Co-Chair)
Biochemistry
Andrew Sweatt, MD (Symposium Committee)
Pulmonary and Critical Care
Ke Yuan, PhD
Pulmonary and Critical Care Medicine
Roham Zamanian, MD
Pulmonary and Critical Care Medicine
Stanford Researchers
Astrid Gillich, PhD
Biochemistry
Kyle Travaglini, BS
Biochemistry